Type 1 Diabetes T1d clinical trials

Explore recruiting type 1 diabetes t1d clinical trials.

Recruiting type 1 diabetes t1d studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Type 1 Diabetes T1d trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

Netherlands, Finland, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D) (βETA PRESERVE)

Czechia, Netherlands, Italy, Germany, Belgium, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Grafalon®therapy within 12 weeks of Type 1 diabetes (T1D) diagnosis in children and young adults to prevent the loss of residual beta cell function: a randomised, double-blind, placebo-controlled dose finding study Acronym: GIRO T1D

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)

Austria, Germany, Poland, Italy, Denmark, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A single-arm, open-label, phase I/II clinical trial of autologous hematopoietic stem and progenitor cells (HSPCs) genetically modified with a lentiviral vector (LVV) encoding for the human programmed death-ligand 1 (hPD-L1) complementary deoxyribonucleic acid (cDNA) for the treatment of patients with type 1 diabetes (T1D) at recent onset and with residual β-cell function (Immunostem)

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Type 1 Diabetes T1d trials by city

Type 1 Diabetes T1d in Toronto Type 1 Diabetes T1d in Vancouver Type 1 Diabetes T1d in Montreal Type 1 Diabetes T1d in Calgary Type 1 Diabetes T1d in Edmonton Type 1 Diabetes T1d in Ottawa Type 1 Diabetes T1d in Winnipeg Type 1 Diabetes T1d in Quebec City Type 1 Diabetes T1d in Hamilton Type 1 Diabetes T1d in Kitchener Type 1 Diabetes T1d in London Type 1 Diabetes T1d in Halifax Type 1 Diabetes T1d in New York Type 1 Diabetes T1d in Los Angeles Type 1 Diabetes T1d in Chicago Type 1 Diabetes T1d in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease